zzlangerhans (99.69)

May 2010

21

2% down in the S&P means 5% down in the average speculative biotech. One has to be philosophical about these temporary paper losses (as long as one isn't way out on margin or long calls) and simply look for more buying opportunities. Claiming to have identified bottoms in a seeming bottomless market may seem like the height of overconfidence, but I wish I had suffered from more overconfidence in March 2009. For those unfamiliar with my trading strategy for 2010, you may find it here. So here are a couple more beaten down biotechs which may provide substantial returns when the market rebounds. [more]

Recs

13

Sorry no news for a while. I've been busy installing a seatbelt on the chair at my computer desk. It's simply not safe checking my portfolio without one these days. Next up is an airbag for my monitor. [more]